Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center for Human Genetics, |
RCV000768482 | SCV000886777 | likely pathogenic | Hypertrophic cardiomyopathy | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Agnes Ginges Centre for Molecular Cardiology, |
RCV000768482 | SCV001430817 | likely pathogenic | Hypertrophic cardiomyopathy | 2018-10-11 | no assertion criteria provided | research | MYH7 Thr318Pro has been reported by another genetic testing laboratory in a de novo case of HCM (ClinVar, SCV000886777.1). We was identified this variant in a HCM proband of Lebanese descent (Ingles J, et al., 2017). The variant segregated to multiple affected family members (5 meiosis). The variant is absent from the Genome Aggregation Database (http://gnomad.broadinstitute.org/). In a large HCM population study Walsh et al., showed that MYH7 variants identified in HCM cases were found to cluster between amino acids 181- 937 (2017), this implies that variants in this region are likely to cause a HCM phenotype. Computational tools SIFT, PolyPhen-2 and MutationTaster predicts this variant to be deleterious. Based on the adapted ACMG criteria (Kelly MA, et al., 2018) this variant is located in mutational hotspot (PM1), is rare in the general population (PM2), has been reported in a de novo case (PM6), segregates with disease (PP1_moderate) and multiple in silico tools predict that this variant is deleterious (PP3), therefore we classify MYH7 Thr318Pro as 'likely pathogenic'. |